Targeting IL-33 in COPD: Who Benefits and What Remains Unknown
Summary
Targeting IL-33 in COPD: Who Benefits and What Remains Unknown HCPLive Physician Views In-Depth: Tozorakimab set to both challenge and grow the COPD market FirstWord Pharma IL-33 Inhibition Reduces COPD Exacerbations in Phase III Trials EMJ Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD HCPLive The Duality of IL-33 in COPD, With Francesca Polverino, MD, PhD HCPLive
Description from News.
Who is covering this
-
Targeting IL-33 in COPD: Who Benefits and What Remains Unknown - HCPLive
Targeting IL-33 in COPD: Who Benefits and What Remains Unknown HCPLive Physician Views In-Depth: Tozorakimab set to both challenge and grow the COPD market FirstWord Pharma IL-33 Inhibition Reduces COPD Exacerbations in Phase III Trials EMJ Q&A: Why IL-33 Matters for Mucus...
Comments
Comments need JavaScript.